JP4950885B2 - 白血病における酵素阻害剤 - Google Patents
白血病における酵素阻害剤 Download PDFInfo
- Publication number
- JP4950885B2 JP4950885B2 JP2007525446A JP2007525446A JP4950885B2 JP 4950885 B2 JP4950885 B2 JP 4950885B2 JP 2007525446 A JP2007525446 A JP 2007525446A JP 2007525446 A JP2007525446 A JP 2007525446A JP 4950885 B2 JP4950885 B2 JP 4950885B2
- Authority
- JP
- Japan
- Prior art keywords
- elastase
- cells
- aml
- cell
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
AML細胞は、外部刺激に独立してエラスターゼを分泌するだけでなく、細胞表面上に均質にアセンブルしたエラスターゼを構造的に発現もする。Cepinskasら、(1999)は、活性好中球にて、可溶性エラスターゼとは異なり、膜結合エラスターゼが触媒活性的であり、循環プロテアーゼによるタンパク質分解に耐性であることを示唆した。したがって、AMLの膜エラスターゼは、循環プロテアーゼによる、タンパク質分解から保護され、AML細胞を、骨髄ECM(細胞外マトリックス)および内皮バリアに浸潤可能にし、循環内へのその散布を促進する。生体内で得られた結果により、膜結合エラスターゼの役割は、BM内皮のような、機械的バリアを介したAML浸潤を補助することだけでなく、3つの異なるエラスターゼ阻害剤MeOSuc−AAPV−CMK(EI)、a1−アンチトリプシンまたは抗エラスターゼ抗体を用いてインビトロ遊走アッセイにて観察されたように、たとえば、細胞骨格再編成および細胞極性化を誘導することによって、エラスターゼが、AML運動性(方向的、SDF−1依存、および突発性遊走両方)のために必要であることが示される。
Claims (1)
- AMLを患っている患者において骨髄から血液へのAML細胞の放出を防止または阻害するための、または
AML細胞の増殖を防止または阻害するための
医薬の製造におけるエラスターゼ阻害剤の使用であって、
該阻害剤が、エラスターゼ−中和抗体またはMeOSuc−AAPV−CMKまたはa1−アンチトリプシンである使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL163453 | 2004-08-10 | ||
IL163453A IL163453A0 (en) | 2004-08-10 | 2004-08-10 | Enzyme inhibitor in leukemia |
PCT/IL2005/000840 WO2006016353A2 (en) | 2004-08-10 | 2005-08-04 | Elastase inhibitor in leukemia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008509903A JP2008509903A (ja) | 2008-04-03 |
JP4950885B2 true JP4950885B2 (ja) | 2012-06-13 |
Family
ID=35124397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007525446A Expired - Fee Related JP4950885B2 (ja) | 2004-08-10 | 2005-08-04 | 白血病における酵素阻害剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090232793A1 (ja) |
EP (1) | EP1781377B1 (ja) |
JP (1) | JP4950885B2 (ja) |
AT (1) | ATE552888T1 (ja) |
AU (1) | AU2005270821B2 (ja) |
CA (1) | CA2576419C (ja) |
ES (1) | ES2381195T3 (ja) |
IL (2) | IL163453A0 (ja) |
NO (1) | NO20071330L (ja) |
WO (1) | WO2006016353A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL148924A (en) * | 2002-03-26 | 2015-06-30 | Mor Research Applic Ltd | Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases |
WO2017049002A1 (en) * | 2015-09-15 | 2017-03-23 | Massachusetts Institute Of Technology | A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system |
CN116087338B (zh) * | 2023-04-10 | 2023-07-14 | 四川省地质矿产勘查开发局一0六地质队 | 一种岩石脆性破坏前兆指标的构建方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2656944B2 (ja) * | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
WO1993000332A1 (en) * | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
GB9307555D0 (en) * | 1992-04-16 | 1993-06-02 | Zeneca Ltd | Heterocyclic compounds |
EP0850252B1 (en) * | 1996-04-12 | 2005-06-08 | American National Red Cross | Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof |
US5760027A (en) * | 1996-12-06 | 1998-06-02 | Research Corporation Technologies, Inc. | Use of 7-alkylidene cephalosporins to inhibit elastase activity |
GB9719172D0 (en) * | 1997-09-09 | 1997-11-12 | Glaxo Group Ltd | Compounds |
JP2005508141A (ja) * | 2001-05-25 | 2005-03-31 | セローノ ジェネティクス インスティテュート ソシエテ アニニム | ヒトcDNAおよびタンパク質、ならびにそれらの使用 |
US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
IL148924A (en) * | 2002-03-26 | 2015-06-30 | Mor Research Applic Ltd | Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases |
AU2003299526A1 (en) * | 2002-06-14 | 2004-06-07 | North Shore - Long Island Jewish Research Institute | Novel human elastases and stress urinary incontinence |
-
2004
- 2004-08-10 IL IL163453A patent/IL163453A0/en unknown
-
2005
- 2005-08-04 US US11/658,967 patent/US20090232793A1/en not_active Abandoned
- 2005-08-04 WO PCT/IL2005/000840 patent/WO2006016353A2/en active Application Filing
- 2005-08-04 AU AU2005270821A patent/AU2005270821B2/en not_active Ceased
- 2005-08-04 AT AT05764348T patent/ATE552888T1/de active
- 2005-08-04 ES ES05764348T patent/ES2381195T3/es active Active
- 2005-08-04 EP EP05764348A patent/EP1781377B1/en active Active
- 2005-08-04 JP JP2007525446A patent/JP4950885B2/ja not_active Expired - Fee Related
- 2005-08-04 CA CA2576419A patent/CA2576419C/en not_active Expired - Fee Related
-
2007
- 2007-02-06 IL IL181183A patent/IL181183A/en not_active IP Right Cessation
- 2007-03-12 NO NO20071330A patent/NO20071330L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1781377A2 (en) | 2007-05-09 |
CA2576419C (en) | 2013-07-02 |
WO2006016353A3 (en) | 2006-07-13 |
US20090232793A1 (en) | 2009-09-17 |
WO2006016353A2 (en) | 2006-02-16 |
IL181183A (en) | 2010-12-30 |
ATE552888T1 (de) | 2012-04-15 |
CA2576419A1 (en) | 2006-02-16 |
ES2381195T3 (es) | 2012-05-24 |
AU2005270821B2 (en) | 2011-06-02 |
IL163453A0 (en) | 2009-02-11 |
EP1781377B1 (en) | 2012-04-11 |
NO20071330L (no) | 2007-03-12 |
JP2008509903A (ja) | 2008-04-03 |
IL181183A0 (en) | 2007-07-04 |
AU2005270821A1 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Galletti et al. | Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression | |
Cao et al. | The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b | |
Infantino et al. | Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells | |
Ratajczak et al. | Modulation of the SDF-1–CXCR4 axis by the third complement component (C3)—Implications for trafficking of CXCR4+ stem cells | |
Marquez-Curtis et al. | The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes | |
Graham et al. | Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease | |
US20140308294A1 (en) | Anti-IL-1R1 Inhibitors For Use in Cancer | |
Isringhausen et al. | Chronic viral infections persistently alter marrow stroma and impair hematopoietic stem cell fitness | |
Nakayama et al. | Lymphotoxin-beta receptor blockade induces inflammation and fibrosis in tolerized cardiac allografts | |
Tavor et al. | Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice | |
JP4950885B2 (ja) | 白血病における酵素阻害剤 | |
Reca et al. | The role of third complement component (C3) in homing of hematopoietic stem/progenitor cells into bone marrow | |
Ratajczak et al. | Further evidence that paroxysmal nocturnal haemoglobinuria is a disorder of defective cell membrane lipid rafts | |
US20180186879A1 (en) | Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion | |
JP2022514867A (ja) | 移植片対宿主病(GvHD)の防止又は処置のための抗CCR7 MABの使用 | |
EP1804828A2 (en) | The use of a protease or a protease inhibitor for the manufacture of medicaments | |
Greenberg | The Role of CD53 in Hematopoietic Development, Stress, and Malignancy | |
US20150366943A1 (en) | MOBILIZATION OF HEMATOPOIETIC STEM CELLS FROM BONE MARROW TO BLOOD USING A COMBINATION OF A ROBO4 RECEPTOR ANTAGONIST AND A CXCR4 ANTAGONIST OR hrVEGF-165 AND A CXCR4 ANTAGONIST | |
Sun | Macrophage-Based Immunotherapies for the Treatment of Multiple Myeloma | |
Rao | Monocytic Cells Mediate Granulocyte-Colony Stimulating Factor-Induced Mobilization of Hematopoietic Stem and Progenitor Cells | |
JP2009219354A (ja) | TIMP−3による造血幹細胞または造血前駆細胞のExvivo/invivo増殖 | |
Ohm | Vascular endothelial growth factor as a mediator of tumor-associated immune suppression | |
Tan | Role of podocalyxin in hematopoiesis and cell migration | |
JP2017146297A (ja) | 慢性骨髄性白血病治療剤及び該治療剤をスクリーニングする方法 | |
Howell | The role of thrombin and protease activated receptor-1 in the pathogenesis of pulmonary fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080723 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120306 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120309 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |